Triple-negative Breast Cancer Therapy Using RNA Nanoparticles Targeting Stem Cell Markers with Anti-miRNA: A Systematic Review and Meta-Analysis

Document Type : Review Article

Authors

1 Department of Internal Medicine, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

2 Department of Gynecology and Obstetrics, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran

Abstract

Background and aim: The present study is the first systematic review and meta-analysis study conducted to investigate the effectiveness of anti-miRNA for triple-negative breast cancer therapy using RNA nanoparticles targeting Stem Cell markers.
Material and methods: The Present study is a systematic review and meta-analysis based on PRISMA 2020 Checklist. A search of PubMed, Scopus, Web of Science, EBSCO, ISI Web of Knowledge, and Embase databases was conducted until April 2023 in order to identify systematic literature. The 95% confidence intervals for effect size have been calculated using the fixed effect model and the inverse-variance method, respectively. A meta-analysis was conducted using Stata/MP v.17.
Results: An initial review was conducted by eliminating duplicate studies, reviewing 103 abstracts, and reviewing the full text of 11 studies by two authors. Finally, two studies were selected. The average hydrodynamic diameter of 3WJ/CD133apt/anti-miR21 nanoparticles was 10.30 nm (ES, 10.30 nm 95% CI 7.10 nm, 13.51nm) with low heterogeneity (I2=0%; P =0.86). Zeta potential was determined to be -25.19 mV (ES, -25.19 mV 95% CI -39.57 mV, -10.81 mV).
Conclusions: 3WJ/CD133apt/anti-miR21 nanoparticles can be considered a suitable option for selecting a Triple-negative breast cancer treatment (TNBC).

Keywords

Main Subjects

References

[1]  Yin L, Duan JJ, Bian XW, Yu SC. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Research. 2020;22:1-3. https://doi.org/10.1186/s13058-020-01296-5.
[2]  Zagami P, Carey LA. Triple negative breast cancer: Pitfalls and progress. NPJ Breast Cancer. 2022;8(1):95. https://doi.org/10.1038/s41523-022-00468-0.
[3]  Costa RE, Oliveira FT, Araújo AL, Vieira SC. Prognostic factors in triple-negative breast cancer: a retrospective cohort. Revista da Associação Médica Brasileira. 2021;67:950-7. https://doi.org/10.1590/1806-9282.20210249.
[4]  Nishimura R, Osako T, Okumura Y, Nakano M, Otsuka H, Fujisue M, et al. Triple negative breast cancer: an analysis of the subtypes and the effects of menopausal status on invasive breast cancer. Journal of Clinical Medicine. 2022;11(9):2331. https://doi.org/10.3390/jcm11092331.
[5]  Cui D, Zhang C, Liu B, Shu Y, Du T, Shu D, et al. Regression of gastric cancer by systemic injection of RNA nanoparticles carrying both ligand and siRNA. Scientific reports. 2015;5(1):1-4. https://doi.org/10.1038/srep10726.
[6]  Binzel DW, Shu Y, Li H, Sun M, Zhang Q, Shu D, et al. Specific delivery of miRNA for high efficient inhibition of prostate cancer by RNA nanotechnology. Molecular Therapy. 2016;24(7):1267-77. https://doi.org/10.1038/mt.2016.85.
[7]  Jasinski DL, Yin H, Li Z, Guo P. Hydrophobic effect from conjugated chemicals or drugs on in vivo biodistribution of RNA nanoparticles. Human Gene Therapy. 2018;29(1):77-86. https://doi.org/10.1089/hum.2017.054.
[8]  Layzer JM, McCaffrey AP, Tanner AK, Huang ZA, Kay MA, Sullenger BA. In vivo activity of nuclease-resistant siRNAs. Rna. 2004;10(5):766-71.
[9]  Manoharan M, Akinc A, Pandey RK, Qin J, Hadwiger P, John M, et al. Unique gene‐silencing and structural properties of 2′‐fluoro‐modified siRNAs. Angewandte Chemie. 2011;123(10):2332-6. https://doi.org/10.1002/ange.201006519.
[10] Zhang Y, Leonard M, Shu Y, Yang Y, Shu D, Guo P, et al. Overcoming tamoxifen resistance of human breast cancer by targeted gene silencing using multifunctional pRNA nanoparticles. ACS nano. 2017;11(1):335-46. https://doi.org/10.1021/acsnano.6b05910.
[11] Yin H, Xiong G, Guo S, Xu C, Xu R, Guo P, et al. Delivery of anti-miRNA for triple-negative breast cancer therapy using RNA nanoparticles targeting stem cell marker CD133. Molecular Therapy. 2019;27(7):1252-61. https://doi.org/10.1016/j.ymthe.2019.04.018.
[12] Collina F, Di Bonito M, Li Bergolis V, De Laurentiis M, Vitagliano C, Cerrone M, et al. Prognostic value of cancer stem cells markers in triple-negative breast cancer. BioMed research international. 2015. https://doi.org/10.1155/2015/158682.
[13] Tugwell P, Tovey D. PRISMA 2020. Journal of Clinical Epidemiology. 2021;134:A5-6. https://doi.org/10.1016/j.jclinepi.2021.04.008.
[14] Tu YK, Needleman I, Chambrone L, Lu HK, Faggion Jr CM. A Bayesian network meta‐analysis on comparisons of enamel matrix derivatives, guided tissue regeneration and their combination therapies. Journal of clinical periodontology. 2012 Mar;39(3):303-14. https://doi.org/10.1111/j.1600-051X.2011.01844.x.
[15] Guo QF, Sun JQ. Therapeutic Effect of Anti-miRNA Mediated by RNA Nanoparticles Targeting CD133 on Triple-Negative Breast Cancer. Science of Advanced Materials. 2022;14(4):803-9. https://doi.org/10.1166/sam.2022.4269.
[16] Merkel OM, Urbanics R, Bedőcs P, Rozsnyay Z, Rosivall L, Toth M, et al. In vitro and in vivo complement activation and related anaphylactic effects associated with polyethylenimine and polyethylenimine-graft-poly (ethylene glycol) block copolymers. Biomaterials. 2011;32(21):4936-42. https://doi.org/10.1016/j.biomaterials.2011.03.035.
 
International Journal of Scientific Research in Dental and Medical Sciences
Volume 5, Issue 2
June 2023
Pages 96-101

Files

History

  • Receive Date: 27 March 2023
  • Revise Date: 12 May 2023
  • Accept Date: 29 May 2023

Share

How to cite

Statistics